South San Francisco, Calif.-based KaloBios, a biotech company that raised $20 million just five months ago, has added another $12 million in a second close of its fourth round of venture capital.

KaloBios has three antibody products in development, each of which targets a specific set of diseases. Two of the candidates, KB001 and KB002, have made it to Phase 2 clinical testing.

The new funding was led by Baxter International, one of the world’s largest healthcare companies. Also participating were MPM Capital, Sofinnova Ventures, Alloy Ventures, GBS Ventures, Singapore Bio-Innovations, Pte., and 5AM Ventures.